KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $2.2 million.

  • Co-Diagnostics' Cash from Investing Activities fell 4782.26% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 169.86%. This contributed to the annual value of $17.1 million for FY2024, which is 1092.95% up from last year.
  • According to the latest figures from Q3 2025, Co-Diagnostics' Cash from Investing Activities is $2.2 million, which was down 4782.26% from $17.1 million recorded in Q2 2025.
  • Co-Diagnostics' 5-year Cash from Investing Activities high stood at $17.1 million for Q2 2025, and its period low was -$53.3 million during Q4 2022.
  • In the last 5 years, Co-Diagnostics' Cash from Investing Activities had a median value of $2.2 million in 2025 and averaged $262790.7.
  • Per our database at Business Quant, Co-Diagnostics' Cash from Investing Activities soared by 105588.29% in 2021 and then plummeted by 507959.19% in 2022.
  • Over the past 5 years, Co-Diagnostics' Cash from Investing Activities (Quarter) stood at $1.1 million in 2021, then plummeted by 5079.59% to -$53.3 million in 2022, then soared by 118.04% to $9.6 million in 2023, then crashed by 97.23% to $266006.0 in 2024, then soared by 717.61% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $17.1 million for Q2 2025, and $7.4 million during Q1 2025.